Drug Profile
DWJ 1366
Alternative Names: DWC20155/DWC20156; DWC20156/DWC20155; DWJ1366Latest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antiulcers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastritis; Gastrointestinal ulcer
Most Recent Events
- 20 Apr 2022 No development reported - Phase-III for Gastritis (Combination therapy) in South Korea (PO)
- 26 Jun 2019 Daewoong Pharmaceutical terminates a phase III trial in Gastritis in South Korea due to lack of efficacy (NCT03184415)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Gastrointestinal ulcer(In volunteers) in South Korea (PO, Tablet)